Biotech presentation design
Your science is complex. Your deck shouldn't be.
We've been designing for life sciences since 2006. Amgen. Gilead. Lilly. Cangene. Labopharm. 3D Signatures. And dozens of companies we'll never be able to name.
Today, over 80% of our projects are biotech. Not because we chose a niche. Because after 20 years of making complex science clear enough to fund, the work kept finding us.
80%+
of projects
are biotech
200+
presentations
designed
1
principal leads
every project
Companies we've designed for
Amgen · Gilead · Lilly · Cangene · Labopharm · BD ·3D Signatures · and many more under NDA
How we think about biotech decks
Every biotech founder faces the same problem: you're explaining science that took years to develop to investors who have 14 other decks to review that afternoon. Too simple and you lose credibility with the scientists in the room. Too complex and you lose the generalists who write the cheques.
We design for that narrow window. One idea per slide. The MOA visualized as a story about what happens to the patient, not a diagram of the pathway. The pipeline structured so investors see a platform, not a single shot on goal. The data presented so it answers the question before the investor asks it.
We also build two versions of every deck: the one you present live, designed to support your voice in the room, and the one that gets forwarded to a partner at 11pm without you there to explain it. They are not the same deck.
What we build
+
Investor pitch decks
Seed through IPO. We've designed more biotech pitch decks in the last two years than most agencies design in a decade. Every one is built around your specific science, your specific audience, and the specific room you're walking into.
IPO roadshow presentations
The highest-stakes presentation your company will ever give. Compliance-aware, financially precise, and designed for institutional investors who read footnotes before headlines.
Conference presentations
JPM. ASCO. BIO. Each one has a different stage, a different format, and a different kind of attention span. A poster session is not a keynote is not a fireside chat. We've designed for all of them.
Board & SAB materials
Quarterly board decks, scientific advisory board presentations, KOL briefings. Data-rich, clean, and built for the audience that already knows the science and will notice if you've oversimplified it.
Partnership & licensing decks
Pitching pharma partners is a different conversation than pitching VCs. Different narrative structure, different data emphasis, same need for a deck that earns the next meeting.
Why biotech teams work with us
+
We already understand your science
We know the difference between a small molecule and a biologic, between a 505(b)(2) and a full NDA, between a Phase Ib expansion cohort and a registrational trial. You won't spend your first meeting educating us. You'll spend it telling us about your molecule.
We've seen what investors actually scrutinize
After hundreds of biotech decks and two decades of working with healthcare-focused VCs, crossover funds, and institutional buyers, we know which slides draw the hardest questions. We design the deck so the data answers before the investor asks.
Confidentiality is our default, not our exception
Over 80% of our work is under NDA. Unpublished clinical data, pre-announcement pipelines, unfiled IP. We handle confidential material every single day. Your science is safe with us.
You work with the principal. That's the whole point.
Ashley has personally designed biotech presentations since 2006. Every engagement is led by her from discovery through delivery. No handoff. No rotating team. No junior designer learning what an IND is on your project.
Our approach
+
Big type. Sharp copy. One idea per slide.
We trust the room. Our slides don't compete with the presenter. They support the story, land the data, and get out of the way. If a slide needs a paragraph to explain itself, it's the wrong slide.
Science as story, not as diagram
Your MOA slide shouldn't look like a textbook figure. It should tell the story of what's broken in the patient and how your molecule fixes it. We turn mechanisms into metaphors that investors remember after the meeting ends.
Every deck is designed for its audience
We match the visual register to the room. A seed pitch to a generalist VC looks different from a partnership deck for a pharma BD team. The science is the same. The way we present it is calibrated to who's listening.
Beyond slides, when it matters
We also prepare presenters and coordinate production for high-stakes moments. Keynotes, roadshows, conference stages. Narrative direction, script review, rehearsal, and when the stage demands it, a network of lighting, audio, and production professionals worldwide.
How we got here
+
We started designing for life sciences in 2006 with AGMs and annual reports for large pharma. The kind of work where a misplaced decimal could move a stock price and an ambiguous chart could trigger a compliance review. That's where we learned precision.
Over two decades, the work deepened. Investor decks. IPO roadshows. Conference presentations. Fundraising materials at every stage, from a preclinical team with a whiteboard and a dream to publicly traded enterprises with global operations and very specific opinions about font sizes.
We didn't choose biotech as a marketing niche. The science kept getting more interesting, the founders kept getting more passionate, and the work kept getting more challenging. So we stayed. Twenty years later, we still get excited about a well-structured pipeline slide. We think that says something.
A note on our portfolio: We can't show you most of our biotech work. That's not a gap. It's how this industry operates. If a design agency can show you their full biotech portfolio, ask their other clients how they feel about that. We're happy to provide direct references instead.
Your science deserves a deck that does it justice.
Whether it's a raise, a roadshow, or a presentation that can't afford to be mediocre, we'd love to hear about what you're building.
